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Abstract
Background: Warfarin is the most widely used oral anticoagulant worldwide, but it has a narrow therapeutic index
which necessitates constant monitoring of anticoagulation response. Previous genome-wide studies have focused
on identifying factors explaining variance in stable dose, but have not explored the initial patient response to
warfarin, and a wider range of clinical and biochemical factors affecting both initial and stable dosing with warfarin.
Methods: A prospective cohort of 711 patients starting warfarin was followed up for 6 months with analyses focusing
on both non-genetic and genetic factors. The outcome measures used were mean weekly warfarin dose (MWD), stable
mean weekly dose (SMWD) and international normalised ratio (INR) > 4 during the first week. Samples were genotyped
on the Illumina Human610-Quad chip. Statistical analyses were performed using Plink and R.
Results: VKORC1 and CYP2C9 were the major genetic determinants of warfarin MWD and SMWD, with CYP4F2 having
a smaller effect. Age, height, weight, cigarette smoking and interacting medications accounted for less than
20 % of the variance. Our multifactorial analysis explained 57.89 % and 56.97 % of the variation for MWD and
SMWD, respectively. Genotypes for VKORC1 and CYP2C9*3, age, height and weight, as well as other clinical
factors such as alcohol consumption, loading dose and concomitant drugs were important for the initial INR
response to warfarin. In a small subset of patients for whom data were available, levels of the coagulation
factors VII and IX (highly correlated) also played a role.
Conclusion: Our multifactorial analysis in a prospectively recruited cohort has shown that multiple factors, genetic
and clinical, are important in determining the response to warfarin. VKORC1 and CYP2C9 genetic polymorphisms are
the most important determinants of warfarin dosing, and it is highly unlikely that other common variants of clinical
importance influencing warfarin dosage will be found. Both VKORC1 and CYP2C9*3 are important determinants of the
initial INR response to warfarin. Other novel variants, which did not reach genome-wide significance, were identified for
the different outcome measures, but need replication.
Background
Warfarin is the most widely used oral anticoagulant
worldwide for the treatment of thromboembolic disor-
ders [1]. The wide inter-individual variability in warfarin
dose requirement, and its narrow therapeutic index
makes the outcome of treatment difficult to predict;
under-anticoagulation can predispose patients to throm-
bosis, while over-anticoagulation increases the risk of
bleeding [2]. A number of interventions have been used
to improve the accuracy of warfarin dosing including
home monitoring [3], computer-based dosing [4], differ-
ent dosing algorithms [5] and more intensive monitoring
[6]. However, despite these measures, accurate warfarin
dosing remains difficult to achieve. Warfarin appears in
the top three of most epidemiological surveys of adverse
reactions causing hospital admission [7]. There is thus a
need to improve the safety of warfarin.
Genetic factors are known to predict warfarin dose
requirements - observational studies have shown that
variation in CYP2C9 and VKORC1, together with body
mass index and age, account for about 50 % of the
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variation in warfarin daily dose requirements [8]. Many
dosing algorithms incorporating both genetic and clin-
ical factors for predicting warfarin doses during initi-
ation and maintenance phases of therapy have been
developed [9]. The FDA has changed the drug label [10]
because of the distinct role genetics plays on warfarin
dose requirement. We have recently undertaken a ran-
domised controlled trial of genotype-guided dosing ver-
sus standard clinical practice [11] - this showed that
genotyping prior to warfarin prescription increased the
time within therapeutic range of international normal-
ised ratio (INR) between 2.0-3.0 by a mean of 7.0 %.
However, the COAG trial [12], conducted in the US,
which used a different algorithmic strategy did not show
any difference in the time within therapeutic INR range
between genotype-guided and clinical dosing algorithms.
There are several possible reasons for the discordant
findings between the two trials [13].
We cannot exclude the possibility that other factors,
either genetic, clinical or biochemical, could improve
personalisation of dosing for warfarin, and thereby its
efficacy and safety. In order to evaluate this, we have
undertaken further analyses of our UK prospective
cohort study [14], where the clinical phenotype of each
patient has been extensively documented, together with
measurement of clinical laboratory tests, and the
vitamin-K dependent coagulation factors. In this paper,
we report on the results of these analyses of the
response to warfarin for both the initiation (first week of
dosing) and maintenance (stable anticoagulation) periods.
Our aim was to identify additional clinical, biochemical
and genetic factors that explain the as yet unexplained 50
% of variation in warfarin dose requirements.
Methods
Ethics, consent and permissions
Blood samples, demographic and clinical data from
patients initiating warfarin for venous thromboembolism
or atrial fibrillation between November 2004 and March
2006 were collected, as described previously [14]. Updated
patient demographics for this extended cohort are avail-
able in Table 1. The study, which conforms to the Declar-
ation of Helsinki, was approved by the Birmingham South
Research Ethics Committee, and each patient provided
informed consent to participate in the study.
Patient follow-up
In this prospective cohort study (EGA accession number
EGAS00001001130), all patients received usual clinical
care with doses being determined either by the anti-
coagulant clinic or attending physician. There were four
fixed study visits for each patient, the first at the time of
initiation of warfarin (index visit), then at 1 week, 8
weeks and 26 weeks of warfarin therapy. The index visit
was before, or within 2 days of commencing warfarin, in
58 % of patients, 26 % of index visits were on the third
day, and the remainder between 4 and 9 days after start-
ing warfarin. Out of 160 patients for which baseline clot-
ting factor and protein levels were measured, only eight
had their index visit after starting warfarin (three on day
1, four on day 2, and one on day 4). To confirm that
timing of initiation relative to index visit did not signifi-
cantly influence baseline clotting factor and protein
levels, patients were stratified and these measurements
compared between strata; trends in clotting factors relat-
ing to index day were also investigated. No significant
trends were found, most probably because of the import-
ant natural population variation observed in the levels of
clotting factors and the small number of patients for
which data were collected after warfarin initiation (data
available on request). Patients also attended anticoagulant
clinic between these four fixed visits as per usual clinical
practice, and the total number of INR measurements var-
ied (median number of INRs per patient: 15; range: 1–65).
At the index visit, patient demographics, smoking his-
tory, current medications and alcohol intake (assessed
using the AUDIT questionnaire [15]) were collected. At
all subsequent follow-up visits, any adverse effects,
changes in warfarin dose or changes in any other medi-
cations since the previous visit were recorded. The list of
medications classified as interacting with warfarin is
available in Additional file 1 on Sheet 1; the interaction
coefficient indicates if the substance reduces (−1) or
potentiates (+1) the action of warfarin; amiodarone’s
coefficient was set to +2 to reflect its strong effect. All
other medications taken by patients and deemed not to
have any effect on warfarin dosing are also listed in
Additional file 1 on Sheet 2.
Outcomes
For this GWAS, we used the following outcome measures:
(1)Mean weekly dose (MWD): mean dose received
weekly during a minimum follow-up time of 14 days
post-loading; the loading period, that is, the first 3
days of treatment, was not included in the
calculations.
(2)Stable mean weekly dose (SMWD): mean weekly
dose for at least three consecutive visits where INRs
were within the targeted range, spanning a minimum
of 14 days and with at least 7 days separating the first
and middle INR measurements, and the middle and
last one.
(3)INR >4.0 in the first week on warfarin.
As the frequency distribution of stable warfarin dose
was skewed, the data were normalised by taking square-
root of stable dose.
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Genotyping, data calling and automated QC
Samples were assayed on the Illumina Human610-Quad
BeadChip using the Infinium HD Super Assay (Illumina,
San Diego, CA, USA); beadchips were scanned with an
iScan. Intensity data, normalised according to the
standard Illumina algorithm, was extracted and geno-
types called using Illuminus [16]. Sample call rate was
calculated and Illuminus re-run using only the samples
with a call rate of at least 90 % (to improve cluster
definition).
Table 1 Summary statistics for all non-genetic factors investigated and outcomes
N Min First quartile Median Mean Third quartile Max
Age (years) 702 18.85 61.87 71.83 68.71 77.65 94.55
Height (cm) 708 125.00 160.00 168.00 168.10 176.00 193.00
Weight (kg) 705 30.00 67.00 79.00 79.58 90.00 160.00
Loading dose (mg) 711 3.00 14.00 21.00 19.44 25.00 32.00
Mean weekly dose (mg/week) 612 4.28 19.70 26.94 27.10 35.19 87.24
Stable mean weekly dose (mg/week) 326 3.50 20.98 26.83 27.78 35.05 119.03
Alcohol consumption score 711 0.00 1.00 2.00 3.79 5.00 38.00
Follow-up time (day) 629 2.00 176.00 182.00 164.70 184.00 277.00
Time to INR over 4 (day) 618 2.00 3.00 3.00 4.19 6.00 7.00
Time to stability (day) 629 2.00 22.00 51.00 55.87 79.50 165.00
Stability duration (day) 326 14.00 42.00 70.00 76.36 103.50 212.00
Haemoglobin (109/L) 144 8.50 12.80 13.95 13.98 15.30 17.70
Platelets (109/L) 143 4.00 204.00 242.00 265.10 300.00 874.00
White cell count (109/L) 144 4.00 5.90 6.80 8.61 8.50 181.00
Neutrophils (109/L) 144 1.70 3.38 4.30 4.56 5.33 13.20
Lymphocytes (109/L) 144 0.60 1.40 1.85 2.02 2.20 27.90
Monocytes (109/L) 144 0.20 0.48 0.60 0.58 0.70 1.20
Eosinophils (109/L) 144 0.00 0.10 0.15 0.20 0.20 0.80
Basophils (109/L) 144 0.00 0.00 0.00 0.02 0.00 0.40
Potassium (mmol/L) 154 2.60 3.80 4.10 4.06 4.30 5.10
Chloride (mmol/L) 157 1.00 99.00 101.00 100.40 103.00 113.00
Bicarbonate (mmol/L) 157 19.00 24.00 26.00 25.83 28.00 39.00
Urea (mmol/L) 158 1.50 4.63 5.90 6.57 7.30 27.40
Creatinine (umol/L) 158 1.00 77.00 92.00 102.70 108.80 773.00
Triglycerides (mmol/L) 148 0.30 0.90 1.20 1.71 1.53 41.00
Albumin (g/L) 157 27.00 39.00 41.00 41.25 44.00 74.00
Total protein (g/L) 159 17.00 70.50 74.00 74.18 78.00 100.00
Billirubin (umol/L) 153 1.00 8.00 10.00 11.85 15.00 30.00
ALT (U/L) 156 5.00 17.00 22.00 29.90 33.00 279.00
Alkaline phosphate (U/L) 156 36.00 67.00 79.00 90.69 104.00 336.00
Gamma GT (U/L) 147 2.00 25.00 36.00 53.79 62.00 344.00
Fibrinogen 65 0.64 3.04 3.70 4.93 4.40 76.00
Factor II (%) 142 8.37 83.42 93.91 92.86 101.40 160.50
Factor V (%) 142 42.44 113.90 135.70 137.80 159.70 237.10
Factor VII (%) 142 0.75 80.15 94.94 96.12 112.20 204.80
Factor IX (%) 142 22.75 109.00 119.40 119.20 134.50 231.50
Factor X (%) 142 44.82 83.71 96.24 98.16 110.60 175.00
Protein C (%) 141 15.83 72.70 85.20 86.63 96.83 199.40
Protein S (%) 142 41.76 123.90 147.20 153.70 177.30 294.70
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Samples having a call rate of less than 95 % or having
autosomal heterozygosity values in the tail of the distri-
bution were excluded. Chromosome X heterozygosity
was used to predict gender (samples with values less
than 4 % are predicted as male, those with values over
15 % are predicted as female); this was compared to the
gender in the original documentation, and discrepancies
resolved or samples excluded. A pairwise comparison
was run for all samples using 400 well-spaced, common
SNPs to identify duplicate samples. Genotypes for each
sample were compared to the molecular fingerprint - a
set of 26 markers typed using the Sequenom platform -
to eliminate the possibility of arraying errors. Identity by
descent (IBD) was calculated for all pairs of samples
using PLINK [17], and one sample was excluded from
each pair for which Pi hat, the proportion IBD, was
superior or equal to 0.1875.
Imputation
Imputation of genotypes was carried out using IMPUTE
V2.1 [18], with the filtered combined set of HapMap 3
release 2 (Feb 2009) and 1000 genomes pilot 1 CEU
(March 2010) [19]. Full details are provided in the
Additional file 2.
CNV calling and QC
A suite of Perl and R (2009) scripts were used as a frame-
work to utilise the R package CNVtools, available from
http://www.bioconductor.org/packages/release/bioc/html/
CNVtools.html [20]. All the steps are detailed in the
Additional file 2.
Kasp genotyping
Genotyping of rs112942398 was performed with a cus-
tom KASP™ genotyping assay (LGC Genomics Ltd.)
using the 68-62 °C touchdown thermal cycling condi-
tions in accordance with the manufacturer’s instructions.
Primer sequences are as follow:
 Primer Allele FAM (G)
AATCCCAGCACTTTGGGAGGC,
 Primer Allele HEX (T)
GTAATCCCAGCACTTTGGGAGGA, and
 Primer Common
GGCTGGATTCGGACCCCTGGA.
Approximately 30 ng genomic DNA was amplified in
a 5 μL reaction mixture containing 1× high ROX KASP
genotyping master mix and 0.07 μL of primer mix. To
improve genotype clustering, the plate was thermally
cycled for an extra 10 cycles with an annealing/elong-
ation temperature of 64 °C. End-point FAM and HEX
signals were read at 30 °C on an ABI 7900HT Fast Real-
Time PCR System (Applied Biosystems). As part of
quality control, negative controls (n = 2) containing
water instead of DNA and 10 % duplicates were included
in the run.
Statistical analyses
Non-genetic variables used for testing univariately for
association with each outcome were age, height, weight,
BMI, gender, loading dose, total follow-up time, dosing
method (manual or computerised), mean target INR,
blood count (haemoglobin, platelets, white cells, neutro-
phils, basophils, lymphocytes, monocytes, eosinophils),
potassium, bicarbonate, chloride, urea, creatinine, tri-
glycerides, albumin, total protein, bilirubin, ALT, alkaline
phosphate, gamma GT, fibrinogen, coagulation factors
II, V, VII, IX and X, Proteins C and S, current smoking
status, number of cigarette smoked per day, ex-smoker
status, alcohol consumption, interacting co-medication
(binary), non-interacting co-medication (binary), sum of
effect of interacting co-medications. The coagulation
factors were measured as described by Jorgensen et al.
[8]. For each variable, either a linear (quantitative out-
comes) or logistic (binary outcome) regression was used
to test for association with outcome in R, and variables
found to be significant univariately (P ≤0.05) were in-
cluded as covariates in the linear or logistic regressions
used to test for association between each SNP and out-
come in turn, carried out in PLINK. When a SNP was
found to be significantly associated with the outcome
tested (at genome-wide significance level, P ≤5 × 10−8), it
was added as a covariate to the multiple regression
model and each SNP was then re-tested for association
with the outcome using this updated model. This
process was repeated until no further SNP reached
genome-wide significance.
To avoid collinearity, all variables were checked for
pairwise correlation using Pearson’s correlation test in R;
pairs with a correlation over 0.7 were deemed highly
correlated and, in the event that they were found signifi-
cantly associated with in any of the investigated out-
comes, only the one variable with the lowest P value was
adjusted for when testing for association with the SNPs.
For each outcome, all significantly associated SNPs at
genome-wide level, as well as the non-genetic variables
found significant univariately were then included together
in a multiple regression model in R. Stepwise variable
selection was applied to the model to establish a final
model. When known variants influencing warfarin dosing
(such as VKORC1 rs9923231, CYP2C9*2 or *3, and
CYP4F2 rs2108622) did not reach genome-wide signifi-
cance, possibly through lack of power, they were added to
the stepwise variable selection in order to determine if
they would indeed improve the final model.
Manhattan and regional plots were prepared using in-
house Python scripts. MWD results were further analysed
Bourgeois et al. Genome Medicine  (2016) 8:2 Page 4 of 12
through the use of IPA (Ingenuity® Systems, www.ingenui
ty.com). Canonical pathways analysis identified the path-
ways from the IPA library of canonical pathways that were
most significant to the dataset. SNPs considered for
canonical pathway analysis had a P value lower than 10−03.
Results
Demographics of patients
The mean age was 69 years (range: 19–95 years) and
55.6 % were men. Patients were treated for atrial fibrilla-
tion (AF; 66.0 %), venous thromboembolism (VTE; 24.5
%), cardiovascular disease (comprising ischaemic heart
disease, congenital cardiac failure, heart valve disease
and other pathologies, total 7.6 %) or other conditions
(comprising respiratory disease, cerebrovascular acci-
dent/transient ischaemic attack, gastrointestinal disease,
neurological disease and other pathologies, total 2.1 %).
Clinical and biochemical factors
Seven patients failed the genotyping rate threshold, nine
failed the heterozygosity criteria, 15 were excluded based
on ethnicity using principal component analysis with
HapMap3 samples as they did not cluster with samples
of European ancestry (data not shown), three had am-
biguous gender, three were excluded because of IBD,
and four patients decided not to participate in the study,
leaving 711 available genotypes for analysis. One hun-
dred patients stopped treatment within the first 2 weeks
of treatment, not allowing their inclusion for mean
weekly dose calculation, though 13 with appropriate
available data were included in INR >4 calculations.
Out of 612 patients with dose and INR information
fitting our SMWD outcome, only 326 (53.3 %) reached
stability over the follow-up period, which covered up to
277 days. One hundred and nineteen (16.6 %) patients
were current smokers (N = 711, mean number of ciga-
rettes = 12.7, sd = 8.9). Out of 625, 116 (18.6 %) patients
had an INR >4.0 during the first week of treatment. Out
of the 711 patients retained for analysis, 160 had baseline
data on full blood count, liver enzymes and coagulation
factor levels. Weight and BMI were highly correlated (R2 =
0.73), as were gender and height (R2 = 0.83), current smok-
ing status and number of cigarettes smoked (R2 = 0.79);
therefore, only the most significant variable of each pair
was kept as a covariate in the regression analyses.
For MWD, age (P = 1.20 × 10−17), height (P = 5.10 ×
10−07), weight (P = 5.02 × 10−10), total follow-up time
(P = 9.41 × 10−03), number of cigarettes smoked per day
(P = 5.34 × 10−06), ex-smoker status (P = 3.01 × 10−04),
alcohol consumption (P = 2.00 × 10−04) as well as the use
of interacting co-medications (P = 6.30 × 10−03), the sum
of interactions (P = 1.38 × 10−04), and the use of medica-
tions not classified as interacting (P = 2.94 × 10−02) were
found significant univariately and therefore adjusted for
when testing for association with each SNP. MWD in-
creased with height and weight, and decreased with age; it
was higher for smokers and increased with the number of
cigarettes smoked each day, while it appeared to be lower
for ex-smokers in comparison to people who never
smoked. MWD was lower in patients taking interacting
co-medications, and decreased as the sum of interactions
increased, but it also appeared to be lower in patients
taking co-medications which are not on the interacting
medications list.
In the subset of samples with extra baseline data,
age (P = 2.06 × 10−05), height (P = 2.43 × 10−03), weight
(P = 3.58 × 10−04), haemoglobin (P = 3.64 × 10−02), baso-
phils (P = 9.20 × 10−03), urea (P = 4.16 × 10−02), ALT (P =
4.71 × 10−02), Factor IX (P = 7.19 × 10−03) and current
smoking status (P = 3.36 × 10−04) were found significant
univariately and included as covariates in the linear
regressions. Though not found univariately significant in
this subset of patients, the use of interacting co-
medications, the sum of interactions, and the use of medi-
cations not classified as interacting were also used as
covariates in the linear regressions.
For SMWD, age (P = 6.20 × 10−09), height (P = 1.72 ×
10−05), weight (P = 2.11 × 10−07) and the use of interact-
ing co-medications (P = 6.62 × 10−03) were found signifi-
cant univariately and adjusted for when testing for
association with each SNP. SMWD increased with
height and weight, and decreased with age, and was
lower in patients taking interacting co-medications.
For INR >4.0 during first week of treatment (INR4),
age (P = 2.77 × 10−03), height (P = 1.53 × 10−02), weight
(P = 2.98 × 10−04), loading dose (P = 7.28 × 10−07), alcohol
consumption (P = 7.76 × 10−03) and use of medications
(during first week of treatment) not classified as interacting
(P = 4.28 × 10−02) were found significant univariately and
included as covariates in the logistic regressions. In
addition to these, in the subset of patient with extra base-
line data, triglycerides (P = 4.97 × 10−02), albumin (P =
4.23 × 10−02) and Factor VII (P = 3.82 × 10−02) were also
found significantly associated with INR4.
GWAS for MWD and SMWD
For warfarin MWD (Table 2 and Fig. 1a), genome-wide sig-
nificant signals clustered on chromosome 16 around
VKORC1, and on chromosome 10 around CYP2C9. The
top signal in VKORC1 was rs9923231 (P = 5.00 × 10−50). In
CYP2C9, the strongest signal, rs4917639 (P = 2.05 × 10−30)
acts as a composite of CYP2C9*2 and *3 [21]; nevertheless,
both *3 (rs1057910, P = 1.24 × 10−23) and *2 (rs1799853,
P = 1.65 × 10−09) also reached genome-wide significance.
After adjustment for genetic and non-genetic covari-
ates, no other SNP reached genome-wide significance
(Fig. 1b). The previously described signal in CYP4F2,
rs2108622 [22, 23] was absent from top hits after
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Table 2 Top signals from linear regressions on mean weekly dose (MWD)
MWD (SD) in mg/week
Variant ID Chr. Pos. Locus Localisation Alleles MAF Beta (SD) P HWE Status Hom. minor Het. Hom. major
rs9923231 16 31015190 VKORC1 Upstream T/C 0.362 −0.875 (0.05335) 5.00E-50* 1.00 Genotyped 16.8 (6.89) 25.99 (9.64) 35.04 (13.63)
rs4917639 10 96715525 CYP2C9 (composite) Intronic C/A 0.208 −0.8334 (0.06864) 2.05E-30* 0.57 Genotyped 14.12 (9.05) 23.77 (9.68) 31.78 (12.92)
rs1057910 10 96731043 CYP2C9 (*3) Non-synonymous coding C/A 0.074 −1.146 (0.1094) 1.24E-23* 0.26 Genotyped 7.55 (1.7) 19.08 (7.69) 29.98 (12.66)
rs1799853 10 96692037 CYP2C9 (*2) Non-synonymous coding A/G 0.126 −0.59 (0.09629) 1.65E-09* 0.01 Genotyped 16.5 (16.94) 23.96 (10.68) 30.09 (13.06)
rs2876443 20 16850210 OTOR, PCSK2 Intergenic G/A 0.378 −0.238 (0.04558) 2.48E-07 0.26 Imputed 25 (10.42) 27.78 (12.82) 30.65 (13.2)
5-164557605 5 164557605 U6, AC008415 Intergenic A/C 0.013 0.9499 (0.1873) 5.34E-07 1.00 Imputed NaN (NA) 37.45 (19.54) 28.24 (12.47)
rs950353 23 30173133 MAGEB1 Intronic A/G 0.076 −0.4548 (0.09473) 2.02E-06 0.29 Imputed 25.39 (10.33) 23.97 (10.45) 29.01 (12.98)
rs13188512 5 7557899 ADCY2 Intronic G/T 0.189 0.2819 (0.05896) 2.21E-06 0.09 Imputed 36.74 (17.71) 30.18 (13.36) 27.37 (12.1)
3-86013074 3 86013074 CADM2 Intronic T/G 0.054 −0.4597 (0.09774) 3.19E-06 1.00 Imputed 16.39 (6.74) 25.6 (13.31) 28.87 (12.69)
rs6571686 14 34290990 BAZ1A Downstream T/A 0.483 −0.2052 (0.04463) 5.22E-06 1.00 Imputed 25.26 (11.44) 29.04 (12.38) 30.14 (14.08)
rs10122258 9 13730846 MPDZ, C9orf146 Intergenic A/T 0.255 0.2302 (0.05111) 8.11E-06 0.69 Imputed 34.96 (15.49) 28.61 (12.57) 27.66 (12.38)
rs2141221 7 94390435 PPP1R9A Intronic T/C 0.460 0.2043 (0.04558) 8.95E-06 0.55 Imputed 31.72 (13.09) 28.43 (12.26) 26.12 (13.07)
rs175811 20 15775473 C20orf133 Intronic C/T 0.167 0.2633 (0.05882) 9.12E-06 0.50 Imputed 34.15 (13.5) 30.82 (13.7) 27.38 (12.23)
rs1496244 11 133052895 OPCML, SPATA19 Intergenic G/A 0.348 0.211 (0.04717) 9.27E-06 0.32 Genotyped 29.14 (10.78) 29.42 (13.32) 27.29 (12.62)
4-128288362 4 128288362 Y RNA, INTU Intergenic A/G 0.034 0.5585 (0.1252) 9.80E-06 0.56 Imputed 40.07 (NA) 32.7 (12.4) 28.22 (12.78)
P values marked with an asterisk were obtained from the regression only adjusting for non-genetic factors, while other P values were obtained from a multiple regression after conditioning on rs9923231, rs1799853
and rs1057910. HWE stands for Hardy-Weinberg Equilibrium and gives the P value of observed number of heterozygous versus expected number of heterozygous, for each variant
Het., heterozygous; Hom. major, homozygous for the major allele; Hom. minor, homozygous for the minor allele
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multiple regression (Table 2 and Fig. 1b; P = 7.70 × 10
−03), explaining only a further 0.5 % of the MWD vari-
ance. Examination of genes at proximity of other signals
of interest did not yield any obvious candidates based
on gene function. Canonical pathway analysis in IPA,
however, using all signals with a P value below 10−03,
highlighted the thrombin signalling pathway, with 12
independent signals with P values ranging from 7.8 × 10
−04 to 2.2 × 10−06 (Table 3), and a P value of 4.6−04for the
pathway as a whole. We performed univariate regressions
to investigate if any of these 12 variants were linked to
coagulation factor levels (data not shown). One variant,
rs2298978, appeared significantly associated with Factor
IX levels (P = 1.26−03, Bonferroni threshold: 4.15−03).
After stepwise regression including all significant non-
genetic covariates as well as rs9923231, rs1057910 and
rs1799853, ex-smoker status and alcohol consumption
were not retained in the final model. Percentage of the
MWD variance explained in the complete model was 57.4
% (breakdown was age 11.20 %, height 3.56 %, weight 5.98
%, follow-up time 1.20 %, number of cigarettes smoked/
day 3.12 %, interacting co-medications 0.98 %, sum of ef-
fects of interacting medications 2.20 %, non-interacting
medications 0.61 %, rs9923231 25.61 %, rs1057910 12.93 %
and rs1799853 3.72 %). Inclusion of rs2108622 (CYP4F2)
brought the total variation explained to 57.89 %.
In the 160 patients for which baseline blood count and
coagulation factor levels were available, age, height,
Fig. 1 Manhattan plots for multiple regressions on MWD only adjusting for non-genetic factors (a) and adjusting for non-genetic and genetic
factors (b). The vertical axis represents the common logarithm of the P value, numbers on the horizontal axis represent the chromosome. Signals
below the genome-wide significance threshold of 5 × 10−08 are represented in green
Table 3 Thrombin signalling pathway as reported by IPA
Gene symbol Entrez gene name dbSNP P value Location Type(s)
ADCY2 Adenylate cyclase 2 (brain) rs13188512 2.22E-06 Plasma membrane Enzyme
PRKCE Protein kinase C, epsilon rs17034610 1.30E-04 Cytoplasm Kinase
ITPR1 Inositol 1,4,5-triphosphate receptor, type 1 rs13082052 1.94E-04 Cytoplasm Ion channel
EGF Epidermal growth factor rs2298978 1.97E-04 Extracellular space Growth factor
ADCY9 Adenylate cyclase 9 rs57119403 3.53E-04 Plasma membrane Enzyme
PLCB1 Phospholipase C, beta 1 (phosphoinositide-specific) rs227885 3.79E-04 Cytoplasm Enzyme
ARHGEF4 Rho guanine nucleotide exchange factor (GEF) 4 rs4322880 3.98E-04 Cytoplasm Other
PLCE1 Phospholipase C, epsilon 1 rs11187789 6.84E-04 Cytoplasm Enzyme
EGFR Epidermal growth factor receptor rs980653 7.14E-04 Plasma membrane Kinase
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 rs28641188 7.42E-04 Cytoplasm Other
PRKCH Protein kinase C, eta rs959729 7.46E-04 Cytoplasm Kinase
MYL9 Myosin, light chain 9, regulatory rs220076 7.80E-04 Cytoplasm Other
Canonical pathway analysis, in IPA, of warfarin MWD multivariate analysis, grouped 12 signals below 10−03 belonging to the thrombin signalling pathway. Gene
symbol, gene name as reported in the Entrez database, the dbSNP variant ID, the P value of the aforementioned variant in the multivariate analysis, the location
and type of the associated protein are reported here
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weight, haemoglobin, basophils, urea, ALT, factor IX and
smoking status were found significant in the univariate
regression on MWD, and included as covariates in the
multiple regression models. As expected given the low
power, only rs9923231 (VKORC1) reached genome-wide
significance, as well as an imputed SNP in the CYP2C9
locus (rs1072753, R2 = 0.61 with rs1057910, CYP2C9*3,
in 1000 genome project pilot 1) (Additional file 3).
CYP2C9*3, instead of the imputed rs1072753, was used
in the stepwise regression. Only age (13.39 %), weight
(7.58 %), Factor IX (4.37 %), smoking status (9.98 %),
rs9923231 (18.15 %) and rs1057910 (14.97 %) were
retained in the final model, explaining a total of 59.64 %
of the MWD variation.
For warfarin SMWD (Additional file 1 Sheet 3), the uni-
variate signals (Fig. 2a) were rs9923231 (P = 9.26 × 10−32)
for VKORC1, and rs4917639 (composite CYP2C9 *2/
*3, P = 5.26 × 10−15) and rs1057910 (CYP2C9*3, P = 3.95 ×
10−09) for CYP2C9, while rs1799853 (CYP2C9*2, P =
4.70 × 10−07) did not reach genome-wide significance.
Despite not reaching genome-wide significance, rs1799853
was included in the multiple regression as it influences
warfarin dose, along with rs9923231 and rs1057910. Three
signals reached genome-wide significance after adjusting
for genetic and non-genetic factors (Fig. 2b): 6–106244024
(P = 6.15 × 10−09), 11–15383178 (P = 6.23 × 10−09) and
rs112942398 (P = 2.40 × 10−08). All these SNPs are the
result of imputation; there is close to no support from
surrounding genotyped SNPs for 11–15383178 and 6–
106244024 (data not shown), unlike for rs112942398
(Additional file 4), which is gene-rich, but none of
the genes had a link to warfarin metabolism or blood
coagulation. To further assess the validity of rs112942398,
94 samples were genotyped using a KASPar custom assay;
10 of the aforementioned samples were given as homozy-
gous for the minor allele by the imputation, and 42 were
given as heterozygous, the remainder being given as
homozygous for the major allele. Four samples failed
genotyping, leaving 90 genotypes available for comparison.
There were 12 discordant genotypes between imputation
and KASPar genotyping, giving an approximate imput-
ation error rate of 13.3 %.
All covariates from the multiple regression remained in
the final model after stepwise regression, with age explain-
ing 9.72 % of SMWD variation, height 4.45 %, weight 7.94
%, interacting co-medications 1.92 %, rs9923231 30.38 %,
rs1057910 8.08 % and rs1799853 3.81 %. The final model
explained 55.27 % of the variation. Inclusion of rs2108622,
retained after stepwise regression, brought the total vari-
ation explained to 56.97 %.
GWAS analysis for INR >4.0 in the first week
Age, height, weight, loading dose, alcohol consumption
and medications not known to interact with warfarin
were significant in the univariate analysis and were
adjusted for when testing for SNP associations. Two
regions harbour signals reaching genome-wide signifi-
cance (Additional file 1 Sheet 4 and Fig. 3a): the lowest
P value was observed for rs2288004 (P = 8.76 × 10−14) on
chromosome 16, an imputed SNP in high LD with
VKORC1’s rs9923231 (R2 = 0.98), followed by rs1072753
(P = 2.85 × 10−08), an imputed SNP on chromosome 10
in high LD with CYP2C9*3 (rs1057910, R2 = 0.78). After
accounting for rs2288004 and rs1072753 and non-gen-
etic factors, no other signal reached genome-wide signifi-
cance (Fig. 3b). Individuals homozygous for rs9923231
minor allele had an odds ratio of 8.04 (4.43–14.90, N = 83)
for having an INR >4.0 during the first week of treatment,
Fig. 2 Manhattan plots for multiple regressions on SMWD only adjusting for non-genetic factors (a) and adjusting for non-genetic and genetic
factors (b). The vertical axis represents the common logarithm of the P value, numbers on the horizontal axis represent the chromosome. Signals
below the genome-wide significance threshold of 5 × 10−08 are represented in green
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while the odds ratio for heterozygous patients was 2.22
(1.34–3.78, N = 287), in comparison to patients homozy-
gous for the major allele (N = 255); similarly, the odds
ratio for patients homozygous for rs1057910 minor
allele was 24.17 (3.66–644.29, N = 6) and 2.93 (1.70–
4.96, N = 74) for heterozygous, reported against
homozygous patients for the major allele (N = 545).
Two signals not quite reaching genome-wide significance
appear in regions of biological relevance to clotting;
rs747180 (P = 1.09 × 10−06) is located in an intron in
APLP2, which has been linked to haemostasis through its
inhibitory effect on Factor XIa [24, 25], and rs6809892 (P =
2.94 × 10−06) is located near TFRC, a gene implicated in the
development of erythrocytes [26].
Sensitivity analyses
There were 33 patients with at least one clinical value
over three standard deviations from the cohort mean.
We repeated all the regression analyses after excluding
these outlier patients; this did not significantly alter any
of our findings (data not shown).
Discussion
Non-genetic factors [27] and two main genetic factors
[21, 28–32] influence warfarin stable dose, with about 50
% of the variance remaining unexplained. Studies have
mainly focused on stable dose, neglecting factors influ-
encing the initial response to warfarin therapy, a period
during which patients are at high risk of over- or under-
anticoagulation [8, 14]. Our prospective study of 714
British patients undergoing warfarin therapy, from initi-
ation to a 6-month follow-up, has the advantage of being
able to capture clinical parameters difficult to assess
through a retrospective study design, as well as
monitoring a wider range of outcomes, such as patient
response at the time of therapy initiation. As this is a
prospective cohort, and to be true to the diversity of
medical conditions encountered in the clinic, no patients
were excluded based on their co-morbidities, no matter
how severe. However, removing patients with outlier
values for clinical data does not significantly change the
results of the regressions.
For both MWD and SMWD, we confirm previous
findings that VKORC1 and CYP2C9 *2 and *3 are the
major genetic determinants of warfarin dose [21, 28–32].
VKORC1 rs9923231 explained between 25.6 % and 30.4
% of the dose variance (MWD and SMWD, respectively),
CYP2C9*3 between 8.1 % and 12.9 %, and CYP2C9*2
between 3.7 % and 3.8 %, all in accordance with
previous findings [32–37]. Unlike in some previous
studies [22, 23] CYP4F2 rs2108622 did not reach
genome-wide significance, but retaining it in the
model explained 0.5 % of MWD and 1.7 % of
SMWD. No other variants reached genome-wide sig-
nificance in the MWD analysis. Pathway analysis of
the top variants post-conditioning for MWD impli-
cated multiple hits in the thrombin signalling path-
way, but none of these variants remained in the
model after stepwise regression, suggesting that they
had little influence on the overall MWD. For SMWD,
three variants remained significant after conditioning:
while two of them are most probably imputation arte-
facts, the third signal, rs112942398, looks like a much
more plausible signal based on its regional plot. How-
ever, this is likely to be an artefact given that its bio-
logical relevance is unclear, it has not been picked up
by other studies [23, 34], and imputation error rate
was high. These data confirm that other genetic
Fig. 3 Manhattan plots for multiple regressions on INR >4 during first week of treatment only adjusting for non-genetic factors (a) and adjusting
for non-genetic and genetic factors (b). The vertical axis represents the common logarithm of the P value, numbers on the horizontal axis represent
the chromosome. Signals below the genome-wide significance threshold of 5 × 10−08 are represented in green
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factors beyond CYP2C9 and VKORC1 are unlikely to
make a strong contribution towards the variance in
warfarin dose.
In terms of clinical factors for SMWD, these were
similar to those previously described in the literature
[14, 27, 38, 39], namely age, height, weight and use of
interacting co-medications. For MWD, we were able to
explore some novel parameters including the follow-up
period, which explained up to 1.2 % of the variance in
dose, demonstrating the importance of an extended
follow-up period on mean weekly dose calculations.
Interacting co-medications explained 1 % of the dose
variance. Since patients on warfarin are on multiple
medications, which may all potentially interact with war-
farin, sometimes with opposite effects, we evaluated the
sum of these interactions which explained up to 2.2 % of
the variance, showing that much greater effect of co-
medications can be determined by taking into account
the effect of all of them. The number of cigarettes
smoked per day explained up to 3.2 % of the variance,
similar to that seen by co-medications. It is possible that
this effect is mediated through the induction of CYP1A2
by cigarette smoke [40], which metabolises R-warfarin.
In the subset of patients with extended clinical data,
for the MWD, two clinical factors, on top of age and
weight, were of importance and retained after stepwise
regression: (a) smoking, rather than the more refined
number of cigarettes per day, was highly significant and
explained a large portion of the variance at about 10 %;
and (b) baseline Factor IX levels explained approxi-
mately 4.4 % of the MWD variance, far more than the
0.5 % explained by rs2108622 (CYP4F2). The impact of
warfarin on the various clotting factor levels, and how
quickly they respond to warfarin, is not clear, and needs
further investigation.
For INR >4.0 during the first week of treatment, only
two genetic factors were important: VKORC1 rs9923231,
with odds ratios of 7.9 and 2.23, for homozygous for the
minor allele and heterozygous patients, respectively, and
CYP2C9*3, with odds ratios of 24.22 and 2.88, respect-
ively. The warfarin loading dose also seems to play an
important role in this outcome measure with a univari-
ate P value of 5.9 × 10−07 – within our cohort there was
variability in loading doses used, ranging from 3 to 32
mg (median: 21 mg, mean: 19.42 mg), adding to the
inter-patient variability in warfarin response. Taken
together, our data indicate the importance of taking
VKORC1 and CYP2C9 genotype into account when de-
termining the loading dose, consistent with our loading
dose algorithm [41], which when tested in the EU-PACT
trial [11] reduced the risk of patients in the genotype-
guided dosing arm having an INR >4.0. Interestingly,
known interacting co-medications did not show a
significant effect on the outcome INR >4.0, while other
co-medications did. The reason for the latter is unclear,
as there were medications from many different thera-
peutic classes present, and thus the most likely explan-
ation is that this is a surrogate for co-morbidities
affecting anticoagulation response. This is consistent
with a recent cross-sectional study from France which
showed that comorbidities worsened the quality of INR
control [42]. In patients with extended baseline data, tri-
glycerides and factor VII levels also affected the risk of
INR >4.0. Factor VII, a vitamin K-dependent clotting
factor, was highly correlated to factor IX. There is lack
of knowledge concerning the inter-individual variation
in Factor VII levels in response to warfarin. Unfortu-
nately, replication of these results remains impossible at
the moment, as no other warfarin study has recorded
such a wide range of clinical factors, and/or measured
baseline clotting factor levels. Furthermore, given the
high cost involved in measuring clotting factor levels,
their use in clinic is unlikely. The regulation of clotting
factors is most probably complex and the genetic vari-
ants involved in such processes are likely to have a low
to moderate impact on warfarin response (below 5 % for
mean dosing), and thus are unlikely to be included in
dosing algorithms unless whole genome sequencing data
become incorporated into patient records. Curiously,
while ALT was found to contribute significantly to over-
anticoagulation during warfarin initiation in a cohort of
patients from Asian descent, it was not significant in our
INR >4 analysis [43]. It was found to be significantly
associated with MWD in our univariate regressions, but
was not retained in the final model. On the other hand,
it is interesting to note that APOE *ε4 was associated
with lower warfarin dose in a cohort of Brazilian patients
[44], possibly echoing our finding about the influence of
triglycerides on over-anticoagulation. Unfortunately,
rs429358, one of the two variants, with rs7412, used to
code this APOE allele, was neither genotyped not
imputed in our cohort, not allowing us to investigate
further if this allele was linked to our findings.
Conclusions
In conclusion, our analysis shows that multiple factors,
genetic and clinical, are important in determining the
response to warfarin, which is perhaps not surprising given
the pharmacology of warfarin. VKORC1 (rs9923231),
CYP2C9 *3 and *2 are the most important genetic factors
influencing warfarin dose, with CYP4F2 (rs2108622) having
a minor effect, with age and BMI being important clinical
covariates. Patients’ smoking habits and the totality of
interacting co-medications, however, also seems to be im-
portant when determining warfarin dose. In relation to
INR >4 after warfarin initiation, VKORC1 and CYP2C9*3
are important in determining the loading dose, together
with alcohol consumption. Realistically, at the present time,
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it would not be possible to evaluate each of the clinical
factors in trials to optimise warfarin dosing. Furthermore,
in a randomised design, confounding clinical factors are
likely to be balanced between two arms. Thus, the trials
which have been undertaken, which take into account
CYP2C9 and VKORC1 genotype, together with age and
BMI in determining dosing algorithms, represent prag-
matic designs in a Northern European population.
Additional files
Additional file 1: Sheet 1. Interaction coefficients of drugs known to
be interacting with warfarin. Drugs known to interact with warfarin were
classified according to their effect on warfarin dosing, with a plus sign for
potentiating drugs, and minus for the opposite effect, the absolute value
representing the scale of the effect. When several of these drugs were
used concomitantly the sum of these coefficients was used. Sheet 2.
List of all concomitant drugs taken by patients. Sheet 3. Top signals
from linear regressions on SMWD. P values marked with an asterisk were
obtained from the regression only adjusting for non-genetic factors, while
other P values where obtained from a multiple regression after conditioning
on rs9923231, rs1799853 and rs1057910. Sheet 4. Top signals from logistic
regressions on INR >4 during first week of treatment. P values marked
with an asterisk were obtained from the regression only adjusting for
non-genetic factors, while other P values where obtained from a multiple
regression after conditioning on rs2288004 and rs1072753. P values for
rs9923231, CYP2C9 *2 and *3 are reported, albeit they were not the most
statistically significant signals in their respective region. 95 % confidence
intervals for odds ratios are indicated in parentheses. (XLSX 28 kb)
Additional file 2: The CNV QC and analysis method. (DOCX 39 kb)
Additional file 3: Manhattan plot for a multiple regression on MWD
with additional non-genetic variables. The vertical axis represents
the common logarithm of the P value, numbers on the horizontal axis
represent the chromosome. Signals below the genome-wide significance
threshold of 10−08 are represented in green. In addition to age, height and
weight, Factor IX levels, smoking status, ALT, urea levels, haemoglobin count
and basophils count were used as covariates in the regression on warfarin
mean dose. (PNG 1601 kb)
Additional file 4: Regional plot of signals around rs112942398. The
left vertical axis represents the absolute value of decimal logarithm
of the P value, the right vertical axis represents the recombination
rate, in centimorgans per megabase, and the horizontal axis
represents the position, in base pairs, along chromosome 10,
according to the NCBI 36 reference. The colour associated with each
signal represents the amount of linkage disequilibrium with the main
signal in the region, the latter being represented on the plot by a purple
diamond; the colour coding is explained in the legend box on the right
of the figure. Genes in the regions are represented by arrows which
indicate their approximate position, length and transcription direction,
the arrow head pointing toward 3’. (PNG 1288 kb)
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